Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii.
Smith AT, Livingston MR, Mai A, Filetici P, Queener SF, Sullivan WJ Jr.
Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartmento di Studi Farmaceutici, Universita degli Studi di Roma "La Sapienza", P.le A. Moro 5, I-00185 Roma, Italy, Istituto di Biologia e Patologia Molecolari CNR, Dip. Genetica e Biologia Molecolare, Universita degli Studi di Roma "La Sapienza", P.le A. Moro 5, I-00185 Roma, Italy.
We report that quinoline derivative MC1626, first described as an inhibitor of the histone acetyltransferase (HAT) GCN5, is active against the protozoan parasite Toxoplasma gondii in vitro. However, MC1626 does not inhibit Toxoplasma GCN5 HATs, nor reduce HAT-mediated activity; rather, this quinoline may target the plastid organelle called the apicoplast.
PMID: 17178801 [PubMed - as supplied by publisher]
Full text here
No comments:
Post a Comment